The aim of the present study is to identify the optimal anticancer agents for use in combination with gene therapy using wild-type (wt) p53 gene transfer. We used adenoviral vectors expressing human wt p53 (AdCAp53) and investigated the effects of wt p53 gene transfer in combination with 12 anticancer agents on a human pulmonary squamous cell carcinoma cell line, NCI-H157, and a human pulmonary large cell carcinoma cell line, NCI-H1299. Solutions containing anticancer agents at various concentrations were added followed by the addition of recombinant adenovirus solutions; after a 5-day incubation period, the anticancer activity was then evaluated by a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide assay. Each 50% inhibitory concentration was calculated based on the dose-response curves. The agents showing a high degree of effectiveness on NCI-H157 cells were cisplatin (CDDP), 5-fluorouracil (5-FU), bleomycin, and 7-ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of irinotecan (CPT-11); conversely, cyclophosphamide and paclitaxel showed a low degree of effectiveness. Based on these data, an isobologram was performed to investigate the interaction between AdCAp53 and some anticancer agents. A supra-additive effect was thus observed for 5-FU and SN-38 on NCI-H157 cells. An additive effect was also observed for CDDP, paclitaxel, bleomycin, and cyclophosphamide on NCI-H157 cells. CDDP, paclitaxel, 5-FU, and SN-38 had an additive effect on NCI-H1299 cells. No drug showed any subadditive or protective effects. These findings suggest that CPT-11 and 5-FU may thus be useful as possible anticancer agents for use in a combination therapy regimen using wt p53 gene transfer. CDDP and CPT-11 had a significant antitumoral effect on H157 cell xenografts of nude mice in vivo. These results indicate that CPT-11 as well as CDDP would be a candidate for the combination of chemotherapy and gene therapy for non-small cell lung cancer. Cancer Gene Therapy (2000) 7, 300 -307
T he loss of wild-type (wt) p53 function is probably the most common genetic aberration in human neoplasms, and this phenomenon has also been reported to increase the resistance of some anticancer agents. 1 Both the transfer of wt p53 to cancer cells and the administration of anticancer drugs are known to induce apoptosis. Theoretically, this combination is thought to improve cancer therapy. Fujiwara et al 2 showed that recombinant adenovirus-mediated transfer of the wt p53 gene into the human non-small cell lung cancer (NSCLC) cell line H358 (p53-deleted) markedly increased the cellular sensitivity of these cells to the anticancer agent cisplatin (CDDP). In contrast, Kimura et al 3 showed that the in vitro chemosensitivity to four different kinds of anticancer agents, including CDDP, etoposide (VP-16), 5-fluorouracil (5-FU), and paclitaxel, was not modulated by the expression of the wt p53 gene. 3 The relationship between p53 status and chemoresensitivity thus remains controversial. In addition, there has yet to be a report in which the optimal combination of anticancer agents and gene therapy by the induction of wt p53 was investigated. In this study, to identify the optimal anticancer agents for use in combination therapy, we investigated the combined efficacy of the adenovirus-mediated transfer of both the wt p53 gene and anticancer agents in vitro and in vivo.
MATERIALS AND METHODS

Cell culture and chemicals
A human pulmonary squamous cell carcinoma cell line, NCI-H157, and a human pulmonary large cell carcinoma cell line, NCI-H1299 (a generous gift of Dr. Adi F. Gazdar, University of Texas Southwestern Medical Center, Dallas, Tex), were both used in this study. The p53 gene of NCI-H157 is mutated (exon 8, codon 298, CAG to TAG) 4 and that of NCI-H1299 is deleted, and both cell lines exhibited a high gene transfer effect when cultured with adenoviral vectors. 5 
Cell growth conditions
NCI-H157 and the NCI-H1299 were grown in RPMI 1640 containing 10% dialyzed fetal bovine serum and penicillin/ streptomycin. The cells were maintained at 37°C in 5% CO 2 in complete humidity.
Adenoviral vector
Replication-defective E1 and E3 adenoviral vectors expressing human wt p53 5, 6 were prepared as described previously. 7 A cDNA coding for human wt p53 (kindly provided by Dr. Vogelstein, Program in Human Genetics, Johns Hopkins Oncology Center, Baltimore, Md) was placed into a cassette cosmid vector, pAdexCA1w (provided by Dr. Saito, University of Tokyo, Tokyo, Japan), under a CA promoter comprising a cytomegalovirus enhancer and chicken ␤-actin promoter (pAdex1w/p53). 8 A recombinant adenovirus was constructed by in vitro homologous recombination in 293 cells using pAdexp53 and the adenovirus DNA-terminal protein complex. 6 The desired recombinant adenovirus, designated AdCAp53 (4 ϫ 10 8 plaque-forming units (PFU)/mL), was purified by ultracentrifugation through a CsCl 2 gradient followed by extensive dialysis. Contamination of wt adenovirus was excluded by the polymerase chain reaction designed for E1 amplification. The titer of the virus stock was assessed by a plaque-formation assay using 293 cells and expressed as plaque-forming units. We also a prepared a control adenovirus that expressed AdCALacZ bacterial ␤-galactosidase and Adex1w but did not express any exogenous genes. 7,9 -11 
XTT assay
The cell proliferation was spectrophotometrically monitored using XTT (Sigma) as described previously. [12] [13] [14] Briefly, cells were placed in 96-well plates and infected with recombinant adenovirus. After 24 hours, the anticancer agents were added. On day 5, 1 mg of XTT and 0.02 mM of N-methylphenazonium methosulfate were added to the plate, and the plate was incubated for 4 hours at 37°C. Absorbance at 450 nm was measured using an automated microplate reader (ImmunoMini NJ-2300, InterMed, Tokyo, Japan).
Isobologram analysis
The effect of the transfer of the wt p53 gene with anticancer agents at a 50% infective dose (ID 50 ) was analyzed using a modification of the isobologram method described previously. [15] [16] [17] Briefly, three isoeffect curves were drawn (mode 1, mode 2a, and mode 2b) based on the dose-response curves of the recombinant adenovirus and the combined drug (Fig 1) . Mode 1 indicates that when the dose of AdCAp53 was chosen, an increased effect was produced by the combined drug. The calculation of the addition was performed by taking the increment in doses, starting from 0, which produced log survivals that added up to ID 50 (hetero-addition). Mode 2a indicates that when the dose of AdCAp53 was chosen, an increment in effect remained to be produced by the combined drug. The calculation of the addition was performed by taking the increment in doses, starting from the point on the doseresponse curves of AdCAp53 at which the effect of its dose had ended and the point that produced log survivals that added up to ID 50 (iso-addition). Similarly, mode 2b indicates that when the dose of combined drug was chosen, an increased effect was produced by AdCAp53. The calculation of the addition was performed by taking the increased doses, starting from the point on the dose-response curve at which its dose had ended, that produced log survivals that added up to ID 50 (iso-addition). Because we do not know whether or not the combined effect of the two drugs is iso-additive, hetero-additive, or intermediate (between iso-and heteroadditive), all possibilities should thus be considered. When the data points indicate a 50% inhibition due to the combination treatment with AdCAp53 and the anticancer agents fall to the left of the envelope (Pa), this combination is thus considered to show a supra-additive interaction (synergism). When the data points of a combination fall in the area surrounded by three lines (envelope of additivity) (Pb), this combination is thus considered to be additive. When the data points fall to the right of the envelope, but are still either within or on the square dotted line (Pc), this combination is thus considered to show a subadditive interaction. When the data points are outside the square (Pd), this combination is thus considered to demonstrate protective interaction. Both the subadditive and protective effects are considered to be antagonistic.
All experiments were repeated at least three times. In each experiment, the dose-response curves of AdCAp53 and the combined drugs were slightly different; however, a similar tendency was observed.
Experimental schedule
On day 0, the cell suspensions were dispensed into the individual wells of a 96-well tissue culture plate. Next, the recombinant adenovirus solutions (50 L) were added at various concentrations at the time of seeding and thereafter were not removed by subsequent media changes; similarly, chemotherapeutic agents added at 24 hours after seeding were not removed with the XTT assay. On day 1, the solutions containing the anticancer agents at various concentrations were added. The plate was subsequently incubated in a humidified atmosphere of 5% CO 2 at 37°C. On day 5, the XTT assay was performed as described above.
Western blot
Aliquots of conditioned medium were applied to sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. The separated proteins were transferred to a nitrocellulose membrane. The membrane was blocked overnight in 5% skimmed milk in tris(hydroxymethyl)aminomethane (Tris)-buffered saline (TBS)/Tween 20. After multiple washes in TBS/Tween 20, the membranes were incubated with the corresponding primary antibody, DO-1 (Ab-6, Oncogene Science, Uniondale, NY) (at a 1/100 dilution for 2 hours). Multiple washes in TBS/Tween 20 were performed before the application of the secondary anti-rabbit antibody (at a 1/1000 dilution for 1 hour). After further washes in TBS/Tween 20 solution, wt p53 protein was detected using the enhanced chemiluminescence Western blotting analysis system (Amersham, Arlington Heights, Ill).
In vivo experiment
NCI-H157 tumor xenografts were established in the subcutaneous spaces of nu/nu mice. An intraperitoneal (i.p.) CDDP (3 mg/kg body weight) or irinotecan (CPT-11) (50 mg/kg body weight) injection was given on day 0 followed by an intratumoral (i.t.) injection of 4 ϫ 10 7 AdCAp53 or AdCALacZ PFU in 100 L of phosphate-buffered saline on days 0, 4, 7, 11, 14, and 18. An i.t. injection of 4 ϫ 10 7 AdCAp53 or AdCALacZ PFU in 100 L of phosphate-buffered saline without the anticancer agents was administered using the same protocol. The tumor sizes were measured every 3 or 4 days for 21 days, and tumor volumes were estimated according to the following formula: A ϫ B 2 , where A and B equal the long and short diameter of tumor xenografts, respectively. Six mice were used for each group.
RESULTS
Dose-response curves of recombinant adenovirus
The dose-response curve of the recombinant adenovirus is presented in Figure 2 . AdCAp53 inhibited the cell growth of NCI-H157 cells and NCI-H1299 cells in a dose-dependent manner. At a concentration of 0.5 multiplicities of infection (MOI) and 0.03 (MOI) for NCI-H157 and NCI-H1299, respectively, cell growth was inhibited by 15% of the control cell growth (ID 15 ). In our preliminary experiments, the cell growth was not influenced by AdLacZ when using higher concentrations of the virus (Յ10 MOI) (data not shown).
IC 50 of each agent with or without AdCAp53
The representative dose-response curves of anticancer agents in the absence or presence of AdCAp53 are shown in Figure 3 . The 50% inhibitory concentration (IC 50 ) of each agent with or without AdCAp53 was calculated based on the dose-response curves ( Table 1) . The IC 50 ((IC 50 ) single agent /(IC 50 ) agentϩAdCAp53 ) ratio ranged from 2.63 to 0.85. In parental (uninfected) cells and in cells infected with AdCALacZ, similar doseresponse curves were observed. In H157 cells, the agents demonstrating a high degree of effectiveness were CDDP, 5-FU, BLM, and SN-38, whereas CPM and paclitaxel showed a low degree of combined effectiveness. In H1299 cells, the agents demonstrating a high degree of effectiveness were CDDP, 5-FU, and SN-38, whereas paclitaxel showed a low degree of combined effectiveness. To investigate the interaction between AdCAp53 and anticancer agents more clearly, an isobologram was performed for some agents based on these data.
Combined effect of adenovirus-mediated transfer of the wt p53 gene with anticancer agents in vitro
The findings of the isobolograms are shown in Figures 4 and 5. For NCI-H157 cells, the combined data points for SN-38 and 5-FU were on the left side of the envelope, indicating a supra-additive effect. The combined data points for CDDP, paclitaxel, CPM, and BLM were within the envelope of additivity. For NCI-H1299 cells, the combined data points for SN-38, 5-FU, CDDP, and paclitaxel were within the envelope of additivity. However, no tested drug was found to be in the area of either subadditivity or protection.
Western blot analysis to detect wt p53
A Western blot analysis was performed on NCI-H157 cells, parental cells, and cells infected with AdCALacZ or AdCAp53 at an MOI of 0.5, with or without IC 50 CDDP, to detect wt p53 (Fig 6) . Parental cells and AdCALacZ-infected cells with or without CDDP could not detect wt p53. The cells infected with AdCAp53 could detect wt p53, but no difference was seen for the presence or absence of CDDP.
Effect of AdCAp53 and combined effect of AdCAp53 with CDDP or CPT-11 in vivo
In in vivo studies, i.t. injections of AdCAp53 without anticancer agents inhibited tumor growth in slightly more than those of AdCALacZ, but no significant differences were observed (Fig 7A) . The i.p. administration of CDDP with AdCAp53 showed substantial growth retardation, and significant differences were seen in the growth rates between AdCAp53 and AdCALacZ ( Fig  7B) from day 12. The i.p. administration of CPT-11 with AdCAp53 showed a similar degree of growth retardation, and significant differences were seen between AdCAp53 and AdCALacZ from day 8 (Fig 7C) .
DISCUSSION
Considerable advances in genetic analyses and in the diagnosis of diseases have recently been made that allow for a more detailed clinical understanding. The use of gene therapy for the treatment of lung cancer is one of these advances, and phase I studies are now being performed using an adenovirus vector expressing wt p53 and CDDP in NSCLC. The use of combination gene therapy with chemotherapy may be a feasible method for future cancer therapy. At present, however, it is unclear as to what role a mutation of the p53 gene may have on the efficacy of anticancer agents. Wahl et al 18 reported that the inactivation of wt p53 confers a 6-to 9-fold increased sensitization to antimicrotubules and such cancer chemotherapeutic agents as paclitaxel. Concur- 19 also reported that, in addition to paclitaxel, p53 inactivation enhances the susceptibility to such therapeutic agents as CBDCA, melphalan, and CDDP. Both studies made use of human foreskin fibroblasts and mouse embryo fibroblasts in which the inactivation of p53 was achieved either by a targeted disruption of the gene or by the acute expression of human papillomavirus-16 E6 or simian virus 40 T-antigen. These experimental conditions may thus be different from the actual clinical setting. Alternatively, Wu and El-Deiry 20 reported that the human ovarian teratocarcinoma cell line PA1 becomes 100 times more resistant to paclitaxel after p53 undergoes targeted degradation by human papillomavirus-16 E6, and this also appears to be true for NCI-H460 lung cancer cells. In addition, Lowe et al 21 reported that p53-deficient mouse embryonic fibroblasts were used to systematically examine the requirements for p53 in cellular sensitivity and resistance to a diverse group of anticancer agents. In a clinical setting, we reported previously that the p53 immunostaining of transbronchial biopsy specimens of lung cancer indicated that p53 overexpression predicts a poor prognosis and chemoresistance in advanced NSCLC. 22, 23 As described above, because the cell lines used and the status of p53 differed greatly from each other, these results remain controversial. In other words, an overexpression of p53 may not induce apoptosis through the same mechanism as endogenous p53, and cell lines may thus acquire unknown mutations that affect the apoptotic activity 24 and DNA repair efficiency of p53. Wu and El-Deiry 20 suggested that the relationship between p53 status and chemoresistance may be tissue-specific, and that even the biological outcome of the loss of wt p53 function in both normal cells and cancer cells may be showed that recombinant adenovirus-mediated transfer of the wt p53 gene into the human NSCLC cell line H358 (p53 deleted) markedly increased the cellular sensitivity of these cells to the anticancer agent CDDP. 2 However, their study did not analyze the combined effect in detail on an isobologram. The purpose of our study was to screen the optimal anticancer agents as combination drugs using gene therapy with wt p53 in human lung cancer cell lines. No previous report has shown the detailed, combined effect of using many clinically available anticancer agents on an isobologram. In our study, we showed that expression of the p53 gene influenced chemosensitivity. SN-38 and 5-FU both had a supraadditive effect according to the isobologram findings, whereas other DNA damaging agents, such as CDDP, BLM, and CPM, had an additive effect. The combination of AdCAp53 with CPT-11 or SN-38 resulted in a high antitumoral effect in vivo. When CDDP with AdCAp53 was administered i.p., there were significant differences from day 12 between AdCAp53 and AdLacZ. In contrast, CPT-11 had similar effect from day 8. In addition, although the CDDP concentration was near a lethal dose, the CPT-11 concentration had a much less lethal dose. These results suggested that CPT-11 combined more effectively with AdCAp53 than CDDP in vivo.
The mechanisms proposed to explain the synergism between SN-38 or 5-FU and AdCAp53 include the following possibilities: in SN-38, the levels of expression of the DNA topoisomerase I (topo I) gene and the topo I protein and its enzymatic activity are important. The cellular levels of DNA topo I and II are known to regulate cellular sensitivity to such topo-targeting agents as camptothecin, VP-16, and teniposide. 25 It has been suggested that wt p53 protein may interact directly with topo I and thus increase its enzymatic activity. Actually, wt p53 has been described as a topo I-binding protein, capable of enhancing the cleavage reaction step of the topo I catalytic cycle in vitro. 26 The binding of p53 and topo I may thus be necessary to enhance the transcriptional activity of p53 in response to DNA damage, and such binding might even occur with other transcriptional transactivators, 27 contributing to wt p53-mediated apoptosis. In 5-FU, thymidylate synthase (TS) is the target enzyme for 5-FU. It functions as the rate-limiting enzyme for the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate and thus is essential in DNA synthesis. 28 Colorectal cancer patients with wt p53 had significantly lower TS levels compared with patients with mutated p53, and specific p53 point mutations have been linked to TS expression levels and resistance to 5-FU. 29 -31 Lee et al 32 reported that wt p53 inhibited TS promoter activity by Ͼ95% but had a strong stimulatory effect on an artificial promoter that contained multiple p53-binding sites. Pritchard et al 33 showed that the 5-FU-induced cell death of intestinal epithelial cells is p53-dependent and suggested that changes in the RNA metabolism initiate events culminating in the expression of p53. As described above, we therefore suggest that some synergistic mechanism exists between SN-38 and AdCAp53, and also between 5FU and AdCAp53.
In our study on NCI-H157 cells, SN-38 and 5-FU both had a supra-additive effect according to the isobologram findings, whereas they had an additive effect on NCI-H1299 cells. Although the reason for these differences is unknown, p53 deletion and mutation differ in their biochemical characteristics. There is no p53 protein on p53-deleted cells. On the other hand, p53 mutants demonstrate defective DNA binding and thus have lost the ability to suppress transformation; in addition, they can form heterotetramers with wt p53, resulting in a dominant negative effect on wt function. 34 Often p53 gene copies are defective in human cancers, and the types of p53 mutation differ from those of such tumor suppressor genes such as Rb and APC. The most common alterations in these genes are deletions and nonsense mutations that eliminate protein expression. In contrast, most p53 alterations involve missense mutations of one allele with a loss or rearrangement of other alleles. This observation suggests that the presence (i.e., a gain of function) of mutated p53 protein, rather than the loss of wt p53 protein, confers a selective growth advantage and promotes clonal expansion. 35 These influences might be responsible for the difference in the tumor cell killing effect between mutant and deleted p53 on the combination of AdCAp53 with SN-38 or 5-FU. In addition, the difference in p53 downstream gene expression, such as bax, gml, bcl-2, gadd45, Rb, and cyclin G, 24,36 -38 may also influence the cell killing effect. 
